Literature DB >> 30587668

Panax notoginseng Saponins Attenuate Oxygen-Glucose Deprivation/Reoxygenation-Induced Injury in Human SH-SY5Y Cells by Regulating the Expression of Inflammatory Factors through miR-155.

Lanqing Meng1, Jun Lin1, Qing Huang1, Ping Liang1, Jianmin Huang1, Chongdong Jian1, Chong Lin1, Xuebin Li1.   

Abstract

Panax notoginseng saponins (PNS) have been widely used in China to treat stroke. Accumulating evidence has found that microRNA (miR)-155 plays critical roles in the pathology of ischemic stroke. Here we investigated whether PNS plays a protective effect against oxygen-glucose deprivation/reoxygenation (OGD/R)-induced focal inflammation and injury in SH-SY5Y cells by regulating miR-155 expression. Treatment with PNS at a concentration less than 160 µg/mL had no effect on the proliferation of SH-SY5Y cell. In OGD/R-induced SH-SY5Y cells, 160 µg/mL PNS treatment promoted cell proliferation and cell cycle progression, as well as decreased inhibited apoptosis and miR-155 expression. However, overexpression of miR-155 attenuated the promotion effects of PNS on cell proliferation and cell cycle, apoptosis inhibition in OGD/R-induced SH-SY5Y cells. Moreover, 160 µg/mL PNS treatment decreased the levels of interleukin-1β (IL-1β), IL-6, and tumor necrosis factor-α (TNF-α) in OGD/R-induced SH-SY5Y cells, whereas overexpression of miR-155 reversed PNS-induced decreases in the levels of IL-1β, IL-6, and TNF-α in OGD/R-treated SH-SY5Y cells. In conclusion, PNS attenuated OGD/R-induced injury in human undifferentiated SH-SY5Y cells by regulating the expression of inflammatory factors through miR-155.

Entities:  

Keywords:  Panax notoginseng saponin; SH-SY5Y; inflammatory factor; microRNA (miR)-155; oxygen–glucose deprivation; reoxygenation

Mesh:

Substances:

Year:  2018        PMID: 30587668     DOI: 10.1248/bpb.b18-00799

Source DB:  PubMed          Journal:  Biol Pharm Bull        ISSN: 0918-6158            Impact factor:   2.233


  6 in total

Review 1.  Efficacy and Safety of Panax Notoginseng Saponins (Xueshuantong) in Patients With Acute Ischemic Stroke (EXPECT) Trial: Rationale and Design.

Authors:  Luda Feng; Fang Han; Li Zhou; Shengxian Wu; Yawei Du; Dandan Zhang; Chi Zhang; Ying Gao
Journal:  Front Pharmacol       Date:  2021-04-22       Impact factor: 5.810

2.  Panax notoginseng saponins reverse P-gp-mediated steroid resistance in lupus: involvement in the suppression of the SIRT1/FoxO1/MDR1 signalling pathway in lymphocytes.

Authors:  Feng Pan; Yue-Jin Li; Ying Lu
Journal:  BMC Complement Med Ther       Date:  2022-01-12

3.  Pharmacological Effect of Panax notoginseng Saponins on Cerebral Ischemia in Animal Models.

Authors:  Chao Dong; Jiawei Li; Ming Zhao; Lin Chen; Xiaochen Zhai; Lingling Song; Jin Zhao; Qiang Sun; Jie Wu; Xiaolu Xie
Journal:  Biomed Res Int       Date:  2022-08-04       Impact factor: 3.246

4.  Changes in nanomechanical properties of single neuroblastoma cells as a model for oxygen and glucose deprivation (OGD).

Authors:  Tomasz Zieliński; Joanna Pabijan; Bartłomiej Zapotoczny; Joanna Zemła; Julita Wesołowska; Joanna Pera; Małgorzata Lekka
Journal:  Sci Rep       Date:  2022-09-29       Impact factor: 4.996

5.  Ginkgolide B Alleviates Learning and Memory Impairment in Rats With Vascular Dementia by Reducing Neuroinflammation via Regulating NF-κB Pathway.

Authors:  Lijuan Huang; Yijie Shi; Liang Zhao
Journal:  Front Pharmacol       Date:  2021-06-17       Impact factor: 5.810

6.  Using mRNA deep sequencing to analyze differentially expressed genes during Panax notoginseng saponin treatment of ischemic stroke.

Authors:  Jun Lin; Ping Liang; Qing Huang; Chongdong Jian; Jianmin Huang; Xionglin Tang; Xuebin Li; Yanling Liao; Xiaohua Huang; Wenhua Huang; Li Su; Lanqing Meng
Journal:  Mol Med Rep       Date:  2020-09-29       Impact factor: 2.952

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.